- Home
- MOB vs IMUX Comparison
MOB vs IMUX Comparison
Compare MOB & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOB
- IMUX
- Stock Information
- Founded
- MOB 2008
- IMUX 2016
- Country
- MOB Israel
- IMUX United States
- Employees
- MOB N/A
- IMUX N/A
- Industry
- MOB Real Estate Investment Trusts
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- MOB Real Estate
- IMUX Health Care
- Exchange
- MOB Nasdaq
- IMUX Nasdaq
- Market Cap
- MOB 83.2M
- IMUX 92.2M
- IPO Year
- MOB 2022
- IMUX N/A
- Fundamental
- Price
- MOB $7.00
- IMUX $0.77
- Analyst Decision
- MOB Strong Buy
- IMUX Strong Buy
- Analyst Count
- MOB 1
- IMUX 5
- Target Price
- MOB $10.00
- IMUX $6.00
- AVG Volume (30 Days)
- MOB 315.1K
- IMUX 1.3M
- Earning Date
- MOB 08-12-2025
- IMUX 11-13-2025
- Dividend Yield
- MOB N/A
- IMUX N/A
- EPS Growth
- MOB N/A
- IMUX N/A
- EPS
- MOB N/A
- IMUX N/A
- Revenue
- MOB $2,826,361.00
- IMUX N/A
- Revenue This Year
- MOB $142.38
- IMUX N/A
- Revenue Next Year
- MOB $99.99
- IMUX N/A
- P/E Ratio
- MOB N/A
- IMUX N/A
- Revenue Growth
- MOB N/A
- IMUX N/A
- 52 Week Low
- MOB $1.28
- IMUX $0.56
- 52 Week High
- MOB $11.02
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- MOB 48.34
- IMUX 49.56
- Support Level
- MOB $6.20
- IMUX $0.67
- Resistance Level
- MOB $6.99
- IMUX $0.79
- Average True Range (ATR)
- MOB 0.90
- IMUX 0.05
- MACD
- MOB -0.08
- IMUX 0.00
- Stochastic Oscillator
- MOB 54.27
- IMUX 56.56
About MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.